Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes
BACKGROUND—Agonistic angiotensin II type I receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be utilized to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker (ARB) tr...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 135; no. 5; pp. 449 - 459 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
by the American College of Cardiology Foundation and the American Heart Association, Inc
31.01.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND—Agonistic angiotensin II type I receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be utilized to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker (ARB) treatment.
METHODS—Demographic and physiologic covariates were measured in a discovery set of community dwelling adults from Baltimore (N=255) and AT1RaAb associations with physical function tests and outcomes assessed. A group from Chicago (N=60) was used for validation of associations and to explore the impact of ARB treatment.
RESULTS—The Baltimore group had 28 subjects with falls, 32 frail subjects and 5 deaths. Higher AT1RaAbs correlated significantly with interleukin-6 (Spearman r = 0.33, P < 0.0001), systolic BP (Spearman r = 0.28, P < 0.0001), body mass index (Spearman r = 0.28, P < 0.0001), weaker grip strength (Spearman r = -0.34, P < 0.01), and slower walking speed (Spearman r = -0.30, P < 0.05). Individuals with high AT1RaAbs were 3.9 (95% CI 1.38-11.0) times more likely to be at high risk after adjusting for age (P<0.05). Every 1 µg/ml increase in AT1RaAbs increased the odds of falling 30% after adjusting for age, gender, BMI and BP. The Chicago group had 46 subjects with falls and 60 deaths. Serum AT1RaAb levels were significantly correlated with grip strength (Spearman r = - 0.57, P < 0.005), walking speed (Spearman r = - 0.47, P< 0.005) and falls (Spearman r = 0.30, P < 0.05). Every 1 µg/ml increase in AT1RaAbs, decreased time to death by 9% after adjusting for age, gender, BMI and BP. Chronic treatment with ARBs was associated with better control of systolic BP and attenuation of decline in both grip strength and time to death.
CONCLUSIONS—In older individuals, higher AT1RaAb levels were associated with inflammation, hypertension and adverse outcomes. ARB treatment may blunt the harm associated with high levels of AT1RaAb. |
---|---|
AbstractList | Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be used to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker treatment.
Demographic and physiological covariates were measured in a discovery set of community-dwelling adults from Baltimore (N=255) and AT1RaAb associations with physical function tests and outcomes assessed. A group from Chicago (N=60) was used for validation of associations and to explore the impact of angiotensin receptor blocker treatment.
The Baltimore group had 28 subjects with falls, 32 frail subjects, and 5 deaths. Higher AT1RaAbs correlated significantly with interleukin-6 (Spearman r=0.33, P<0.0001), systolic blood pressure (Spearman r=0.28, P<0.0001), body mass index (Spearman r=0.28, P<0.0001), weaker grip strength (Spearman r=-0.34, P<0.01), and slower walking speed (Spearman r=-0.30, P<0.05). Individuals with high AT1RaAbs were 3.9 (95% confidence interval, 1.38-11.0) times more likely to be at high risk after adjusting for age (P<0.05). Every 1 µg/mL increase in AT1RaAbs increased the odds of falling 30% after adjusting for age, sex, body mass index, and blood pressure. The Chicago group had 46 subjects with falls and 60 deaths. Serum AT1RaAb levels were significantly correlated with grip strength (Spearman r=-0.57, P<0.005), walking speed (Spearman r=-0.47, P<0.005), and falls (Spearman r=0.30, P<0.05). Every 1 µg/mL increase in AT1RaAbs, decreased time to death by 9% after adjusting for age, sex, body mass index, and blood pressure. Chronic treatment with angiotensin receptor blockers was associated with better control of systolic blood pressure and attenuation of decline in both grip strength and time to death.
In older individuals, higher AT1RaAb levels were associated with inflammation, hypertension, and adverse outcomes. Angiotensin receptor blocker treatment may blunt the harm associated with high levels of AT1RaAb. Background: Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be used to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker treatment. Methods: Demographic and physiological covariates were measured in a discovery set of community-dwelling adults from Baltimore (N=255) and AT1RaAb associations with physical function tests and outcomes assessed. A group from Chicago (N=60) was used for validation of associations and to explore the impact of angiotensin receptor blocker treatment. Results: The Baltimore group had 28 subjects with falls, 32 frail subjects, and 5 deaths. Higher AT1RaAbs correlated significantly with interleukin-6 (Spearman r =0.33, P <0.0001), systolic blood pressure (Spearman r =0.28, P <0.0001), body mass index (Spearman r =0.28, P <0.0001), weaker grip strength (Spearman r =–0.34, P <0.01), and slower walking speed (Spearman r =–0.30, P <0.05). Individuals with high AT1RaAbs were 3.9 (95% confidence interval, 1.38–11.0) times more likely to be at high risk after adjusting for age ( P <0.05). Every 1 µg/mL increase in AT1RaAbs increased the odds of falling 30% after adjusting for age, sex, body mass index, and blood pressure. The Chicago group had 46 subjects with falls and 60 deaths. Serum AT1RaAb levels were significantly correlated with grip strength (Spearman r =–0.57, P <0.005), walking speed (Spearman r =–0.47, P <0.005), and falls (Spearman r =0.30, P <0.05). Every 1 µg/mL increase in AT1RaAbs, decreased time to death by 9% after adjusting for age, sex, body mass index, and blood pressure. Chronic treatment with angiotensin receptor blockers was associated with better control of systolic blood pressure and attenuation of decline in both grip strength and time to death. Conclusions: In older individuals, higher AT1RaAb levels were associated with inflammation, hypertension, and adverse outcomes. Angiotensin receptor blocker treatment may blunt the harm associated with high levels of AT1RaAb. BACKGROUND—Agonistic angiotensin II type I receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be utilized to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker (ARB) treatment. METHODS—Demographic and physiologic covariates were measured in a discovery set of community dwelling adults from Baltimore (N=255) and AT1RaAb associations with physical function tests and outcomes assessed. A group from Chicago (N=60) was used for validation of associations and to explore the impact of ARB treatment. RESULTS—The Baltimore group had 28 subjects with falls, 32 frail subjects and 5 deaths. Higher AT1RaAbs correlated significantly with interleukin-6 (Spearman r = 0.33, P < 0.0001), systolic BP (Spearman r = 0.28, P < 0.0001), body mass index (Spearman r = 0.28, P < 0.0001), weaker grip strength (Spearman r = -0.34, P < 0.01), and slower walking speed (Spearman r = -0.30, P < 0.05). Individuals with high AT1RaAbs were 3.9 (95% CI 1.38-11.0) times more likely to be at high risk after adjusting for age (P<0.05). Every 1 µg/ml increase in AT1RaAbs increased the odds of falling 30% after adjusting for age, gender, BMI and BP. The Chicago group had 46 subjects with falls and 60 deaths. Serum AT1RaAb levels were significantly correlated with grip strength (Spearman r = - 0.57, P < 0.005), walking speed (Spearman r = - 0.47, P< 0.005) and falls (Spearman r = 0.30, P < 0.05). Every 1 µg/ml increase in AT1RaAbs, decreased time to death by 9% after adjusting for age, gender, BMI and BP. Chronic treatment with ARBs was associated with better control of systolic BP and attenuation of decline in both grip strength and time to death. CONCLUSIONS—In older individuals, higher AT1RaAb levels were associated with inflammation, hypertension and adverse outcomes. ARB treatment may blunt the harm associated with high levels of AT1RaAb. BACKGROUNDAgonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs could be used to stratify patient risk and to identify patients who can benefit from angiotensin receptor blocker treatment. METHODSDemographic and physiological covariates were measured in a discovery set of community-dwelling adults from Baltimore (N=255) and AT1RaAb associations with physical function tests and outcomes assessed. A group from Chicago (N=60) was used for validation of associations and to explore the impact of angiotensin receptor blocker treatment. RESULTSThe Baltimore group had 28 subjects with falls, 32 frail subjects, and 5 deaths. Higher AT1RaAbs correlated significantly with interleukin-6 (Spearman r=0.33, P<0.0001), systolic blood pressure (Spearman r=0.28, P<0.0001), body mass index (Spearman r=0.28, P<0.0001), weaker grip strength (Spearman r=-0.34, P<0.01), and slower walking speed (Spearman r=-0.30, P<0.05). Individuals with high AT1RaAbs were 3.9 (95% confidence interval, 1.38-11.0) times more likely to be at high risk after adjusting for age (P<0.05). Every 1 µg/mL increase in AT1RaAbs increased the odds of falling 30% after adjusting for age, sex, body mass index, and blood pressure. The Chicago group had 46 subjects with falls and 60 deaths. Serum AT1RaAb levels were significantly correlated with grip strength (Spearman r=-0.57, P<0.005), walking speed (Spearman r=-0.47, P<0.005), and falls (Spearman r=0.30, P<0.05). Every 1 µg/mL increase in AT1RaAbs, decreased time to death by 9% after adjusting for age, sex, body mass index, and blood pressure. Chronic treatment with angiotensin receptor blockers was associated with better control of systolic blood pressure and attenuation of decline in both grip strength and time to death. CONCLUSIONSIn older individuals, higher AT1RaAb levels were associated with inflammation, hypertension, and adverse outcomes. Angiotensin receptor blocker treatment may blunt the harm associated with high levels of AT1RaAb. |
Author | Xue, Qian-Li Hamilton, Robert G Bennett, David A Walston, Jeremy D Fedarko, Neal S Abadir, Peter M Powell, Laura J Jain, Alka Tian, Jing Finucane, Thomas |
AuthorAffiliation | 1 Biology of Healthy Aging Program, Division of GeriatricMedicine and Gerontology, Department of Medicine; 2 Center on Aging and Health; 3 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; 4 Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; 5 Rush Institute on Healthy Aging, Rush University Medical Center, Chicago, IL |
AuthorAffiliation_xml | – name: 1 Biology of Healthy Aging Program, Division of GeriatricMedicine and Gerontology, Department of Medicine; 2 Center on Aging and Health; 3 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; 4 Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; 5 Rush Institute on Healthy Aging, Rush University Medical Center, Chicago, IL – name: 3 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD – name: 5 Rush Institute on Healthy Aging, Rush University Medical Center, Chicago, IL, USA – name: 1 Biology of Healthy Aging Program, Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University, Baltimore, MD – name: 2 Center on Aging and Health, Johns Hopkins University, Baltimore, MD – name: 4 Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD |
Author_xml | – sequence: 1 givenname: Peter surname: Abadir middlename: M fullname: Abadir, Peter M organization: 1 Biology of Healthy Aging Program, Division of GeriatricMedicine and Gerontology, Department of Medicine; 2 Center on Aging and Health; 3 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; 4 Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; 5 Rush Institute on Healthy Aging, Rush University Medical Center, Chicago, IL – sequence: 2 givenname: Alka surname: Jain fullname: Jain, Alka – sequence: 3 givenname: Laura surname: Powell middlename: J fullname: Powell, Laura J – sequence: 4 givenname: Qian-Li surname: Xue fullname: Xue, Qian-Li – sequence: 5 givenname: Jing surname: Tian fullname: Tian, Jing – sequence: 6 givenname: Robert surname: Hamilton middlename: G fullname: Hamilton, Robert G – sequence: 7 givenname: David surname: Bennett middlename: A fullname: Bennett, David A – sequence: 8 givenname: Thomas surname: Finucane fullname: Finucane, Thomas – sequence: 9 givenname: Jeremy surname: Walston middlename: D fullname: Walston, Jeremy D – sequence: 10 givenname: Neal surname: Fedarko middlename: S fullname: Fedarko, Neal S |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27903588$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUU1vEzEQtVARTQN_AZkbly3-WMe7B5CWQGmkiEhV4Gp5vbOJycYOtrdV_30dUip64zSamffejN67QGfOO0DoHSWXlM7oh_niZv5j2awXq-_NdXOcXRLGeCVeoAkVrCxKweszNCGE1IXkjJ2jixh_5XbGpXiFzpmsCRdVNUG7LzYafwvhHmvX4Z96sJ1O1jvse9xsvLMxWYMbt7E-gYvW4RswcEg-4GZMXrtkW99ZiFhH_Nn6vQ47CPEPvcu6EfBqTMbvIb5GL3s9RHjzWKdoffV1Pb8ulqtvi3mzLEwppShMx0wrZSckL4UsayJqLjoxq7kxNW9Nz3vWCVFTSspKSloCnWlJ28pIBj3nU_TpJHsY2z10BlwKelCHYPNv98prq55vnN2qjb9VglWCSZYF3j8KBP97hJjUPpsEw6Ad-DEqWpWCCcayy1NUn6Am-BgD9E9nKFHHrNTzrI4zdcoqc9_---cT8284GfDxBLjzQ8pO7obxDoLagh7S9j8OPAC5tqjT |
CitedBy_id | crossref_primary_10_3233_JAD_179939 crossref_primary_10_1080_14767058_2020_1846709 crossref_primary_10_1016_j_exger_2021_111655 crossref_primary_10_1016_j_humimm_2019_04_012 crossref_primary_10_1007_s40618_024_02412_4 crossref_primary_10_1042_CS20171485 crossref_primary_10_1016_j_jaut_2021_102683 crossref_primary_10_3389_fnins_2020_586314 crossref_primary_10_1161_JAHA_123_032441 crossref_primary_10_1161_JAHA_123_032672 crossref_primary_10_1016_j_jtauto_2019_100008 crossref_primary_10_1093_ajh_hpaa071 crossref_primary_10_1007_s40520_022_02247_0 crossref_primary_10_1001_jamanetworkopen_2021_27587 crossref_primary_10_1007_s11010_024_05043_8 crossref_primary_10_14336_AD_2018_0919 crossref_primary_10_1186_s13578_023_01063_x crossref_primary_10_1007_s12026_017_8963_6 crossref_primary_10_1161_CIRCRESAHA_123_321883 crossref_primary_10_3390_ijms23020927 crossref_primary_10_1089_mab_2024_29018_editorial crossref_primary_10_3892_mmr_2022_12867 crossref_primary_10_4252_wjsc_v13_i10_1513 |
Cites_doi | 10.1016/j.mce.2008.08.032 10.1038/ajh.2011.113 10.1136/bmj.f6564 10.1093/gerona/56.3.M146 10.1186/s13395-015-0047-5 10.1093/gerona/59.3.M242 10.1056/NEJMoa035717 10.1016/j.cger.2010.08.004 10.2174/156720512801322573 10.1016/j.colsurfb.2008.11.032 10.1007/s00223-014-9894-z 10.1016/S1357-2725(02)00271-6 10.1016/j.autrev.2004.07.002 10.1139/y02-160 10.1172/JCI4106 10.1097/00004872-200018070-00017 10.2174/156720512801322663 10.2165/00007256-200838120-00008 10.1111/j.1532-5415.2007.01186.x 10.1146/annurev.med.51.1.245 10.4049/jimmunol.132.6.2807 10.1161/HYPERTENSIONAHA.113.01648 10.1172/JCI36703 10.1089/jir.2010.0043 10.1016/S0025-7125(05)70157-7 10.1016/j.peptides.2012.09.016 10.1001/jamainternmed.2013.14764 10.1016/j.amjhyper.2004.03.306 10.1016/S0735-1097(00)01138-4 10.1016/j.cellsig.2008.10.011 10.1001/archinte.162.20.2333 10.1056/NEJM200211283472220 10.1007/s00251-002-0453-9 10.1007/s11906-007-0023-5 10.1126/scitranslmed.3002227 10.1152/ajpregu.00525.2011 10.1089/ars.2006.8.572 |
ContentType | Journal Article |
Copyright | 2016 by the American College of Cardiology Foundation and the American Heart Association, Inc. 2016 American Heart Association, Inc. |
Copyright_xml | – notice: 2016 by the American College of Cardiology Foundation and the American Heart Association, Inc. – notice: 2016 American Heart Association, Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1161/CIRCULATIONAHA.116.022385 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 459 |
ExternalDocumentID | 10_1161_CIRCULATIONAHA_116_022385 27903588 10.1161/CIRCULATIONAHA.116.022385 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR001079 – fundername: NCI NIH HHS grantid: R01 CA149273 – fundername: NIA NIH HHS grantid: P30 AG021334 – fundername: NIA NIH HHS grantid: K23 AG035005 |
GroupedDBID | - .XZ .Z2 01R 0R 1AW 1J1 29B 2WC 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O 7O~ 8RP AAAXR AAMOA AAMTA AAPBV AARTV AAWTL AAXQO ABBUW ABFLS ABOCM ABPMR ABPTK ABUFD ABXVJ ABZAD ACDDN ACEWG ACGFS ACRKK ACWDW ACWRI ACXNZ ADBBV ADCYY AE3 AENEX AFCHL AFUWQ AHMBA AHULI AHVBC AIJEX AJIOK ALMA_UNASSIGNED_HOLDINGS AMJPA ASCII ASPBG AVWKF AWKKM AZFZN BAWUL BOYCO BQLVK BYPQX C45 CS3 DIK DU5 E3Z EBS EJD EX3 F2K F2L F2M F2N F5P GX1 H0 H0~ H1 H13 HZ IKYAY IN IN~ JF9 JG8 JK3 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O0- O9- OAG OAH OBH OCB ODA OGEVE OHASI OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWW OWY OXXIT P2P PQEST PQQKQ RAH RHF RIG RLZ RSW S4R S4S UPT V2I W2D WH7 WOQ WOW X3V X3W XZ YZZ Z2 ZA5 ZY1 ~H1 --- .-D .3C 0R~ 0ZK 18M 2FS 354 6PF AAAAV AAGIX AAHPQ AAIQE AAJCS AAQKA AASCR AASOK AASXQ AAUEB ABASU ABDIG ABJNI ABQRW ABVCZ ACCJW ACGFO ACILI ACOAL ACXJB ADGGA ADHPY AE6 AEBDS AEETU AFDTB AFEXH AFSOK AGINI AHOMT AHQNM AHRYX AINUH AJNWD AKULP ALMTX AMKUR AMNEI AOHHW AYCSE CGR CUY CVF DIWNM ECM EEVPB EIF ERAAH FCALG GNXGY GQDEL HLJTE HZ~ IKREB IPNFZ K-A K-F NPM ODMTH OHH OHYEH OJAPA OLB OWBYB OWU OWV OWX OWZ T8P TEORI TR2 TSPGW VVN W3M W8F XXN XYM YFH YOC YSK YYM ZFV AAYXX AJZMW CITATION 7X8 5PM ZZMQN |
ID | FETCH-LOGICAL-c4775-cd2cb77d5734574905935d5693cc93bcf3f2d559110487714e16a71b8c72ef33 |
ISSN | 0009-7322 |
IngestDate | Tue Sep 17 21:04:05 EDT 2024 Fri Aug 16 06:27:38 EDT 2024 Fri Aug 23 02:57:34 EDT 2024 Fri May 24 00:02:29 EDT 2024 Thu Aug 13 19:54:13 EDT 2020 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | mortality angiotensin receptor blockers aging inflammation autoantibodies |
Language | English |
License | 2016 American Heart Association, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4775-cd2cb77d5734574905935d5693cc93bcf3f2d559110487714e16a71b8c72ef33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.116.022385 |
PMID | 27903588 |
PQID | 1845252245 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5285272 proquest_miscellaneous_1845252245 crossref_primary_10_1161_CIRCULATIONAHA_116_022385 pubmed_primary_27903588 wolterskluwer_health_10_1161_CIRCULATIONAHA_116_022385 |
ProviderPackageCode | OVOZU L-C C45 7O~ AARTV ABPMR OLH ASCII BYPQX OLG AAMOA ODA ABZAD ABBUW JK3 H0~ 1J1 OLV OLU JG8 OLW OLZ OLY F2K F2M F2L F2N OHASI AHVBC KMI OGEVE K8S OVLEI AJIOK OPUJH V2I .XZ S4R S4S 4Q1 OAG 4Q2 OVDNE 4Q3 AMJPA OAH OVD 71W AHULI ACEWG .Z2 N~7 IKYAY OVIDH AWKKM 40H N~B OBH X3V X3W ACDDN ACWRI BOYCO AIJEX AAXQO ~H1 AAMTA AAAXR OWW OCB OWY 01R ACXNZ OL1 AFCHL ABXVJ IN~ KD2 OXXIT 77Y ACWDW JF9 |
PublicationCentury | 2000 |
PublicationDate | 2017-01-31 |
PublicationDateYYYYMMDD | 2017-01-31 |
PublicationDate_xml | – month: 01 year: 2017 text: 2017-01-31 day: 31 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2017 |
Publisher | by the American College of Cardiology Foundation and the American Heart Association, Inc |
Publisher_xml | – name: by the American College of Cardiology Foundation and the American Heart Association, Inc |
References | 22170620 - Am J Physiol Regul Integr Comp Physiol. 2012 Mar 1;302(5):R518-30 12073143 - Immunogenetics. 2002 Jun;54(3):141-57 23032352 - Peptides. 2012 Dec;38(2):437-45 21716327 - Am J Hypertens. 2011 Oct;24(10):1143-8 12456865 - N Engl J Med. 2002 Nov 28;347(22):1806 11253156 - J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56 15652781 - Autoimmun Rev. 2005 Jan;4(1):61-5 21093722 - Clin Geriatr Med. 2011 Feb;27(1):53-65 18824067 - Mol Cell Endocrinol. 2009 Apr 29;302(2):219-29 17442224 - Curr Hypertens Rep. 2007 Apr;9(2):128-32 26180626 - Skelet Muscle. 2015 Jul 15;5:21 21288138 - J Interferon Cytokine Res. 2011 Jun;31(6):471-4 18992324 - Cell Signal. 2009 Mar;21(3):378-83 10930193 - J Hypertens. 2000 Jul;18(7):945-53 24567036 - JAMA Intern Med. 2014 Apr;174(4):588-95 10503059 - Med Clin North Am. 1999 Sep;83(5):1173-94 11216960 - J Am Coll Cardiol. 2001 Feb;37(2):440-4 21562229 - Sci Transl Med. 2011 May 11;3(82):82ra37 12418947 - Arch Intern Med. 2002 Nov 11;162(20):2333-41 12676174 - Int J Biochem Cell Biol. 2003 Jun;35(6):881-900 16677101 - Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):572-81 22471860 - Curr Alzheimer Res. 2012 Jul;9(6):628-45 17537086 - J Am Geriatr Soc. 2007 Jun;55(6):864-71 24201165 - BMJ. 2013 Nov 07;347:f6564 15031308 - J Gerontol A Biol Sci Med Sci. 2004 Mar;59(3):242-8 12710518 - Can J Physiol Pharmacol. 2003 Feb;81(2):79-83 10194466 - J Clin Invest. 1999 Apr;103(7):945-52 24041954 - Hypertension. 2013 Nov;62(5):886-92 10774463 - Annu Rev Med. 2000;51:245-70 15703421 - N Engl J Med. 2005 Feb 10;352(6):558-69 25055749 - Calcif Tissue Int. 2014 Oct;95(4):308-16 19157807 - Colloids Surf B Biointerfaces. 2009 Apr 1;70(1):1-6 6327810 - J Immunol. 1984 Jun;132(6):2807-12 19026021 - Sports Med. 2008;38(12):1065-79 22471867 - Curr Alzheimer Res. 2012 Jul;9(6):646-63 19197138 - J Clin Invest. 2009 Mar;119(3):524-30 9316215 - Semin Nephrol. 1997 Sep;17(5):467-91 e_1_3_4_3_2 e_1_3_4_2_2 e_1_3_4_9_2 e_1_3_4_8_2 e_1_3_4_7_2 e_1_3_4_41_2 e_1_3_4_6_2 e_1_3_4_40_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_23_2 e_1_3_4_21_2 e_1_3_4_42_2 e_1_3_4_26_2 e_1_3_4_27_2 e_1_3_4_24_2 e_1_3_4_25_2 e_1_3_4_28_2 e_1_3_4_29_2 e_1_3_4_30_2 e_1_3_4_11_2 e_1_3_4_34_2 e_1_3_4_33_2 e_1_3_4_32_2 e_1_3_4_10_2 e_1_3_4_31_2 Dechend R (e_1_3_4_12_2) 2012; 24 e_1_3_4_15_2 e_1_3_4_38_2 e_1_3_4_16_2 e_1_3_4_37_2 e_1_3_4_13_2 e_1_3_4_36_2 e_1_3_4_14_2 e_1_3_4_35_2 Weber KT (e_1_3_4_5_2) 1997; 17 e_1_3_4_19_2 (e_1_3_4_20_2) 1997; 62 e_1_3_4_17_2 e_1_3_4_18_2 e_1_3_4_39_2 |
References_xml | – ident: e_1_3_4_23_2 doi: 10.1016/j.mce.2008.08.032 – ident: e_1_3_4_32_2 doi: 10.1038/ajh.2011.113 – ident: e_1_3_4_27_2 doi: 10.1136/bmj.f6564 – ident: e_1_3_4_17_2 doi: 10.1093/gerona/56.3.M146 – ident: e_1_3_4_40_2 doi: 10.1186/s13395-015-0047-5 – ident: e_1_3_4_38_2 doi: 10.1093/gerona/59.3.M242 – ident: e_1_3_4_8_2 doi: 10.1056/NEJMoa035717 – ident: e_1_3_4_28_2 doi: 10.1016/j.cger.2010.08.004 – ident: e_1_3_4_18_2 doi: 10.2174/156720512801322573 – ident: e_1_3_4_21_2 doi: 10.1016/j.colsurfb.2008.11.032 – ident: e_1_3_4_39_2 doi: 10.1007/s00223-014-9894-z – ident: e_1_3_4_6_2 doi: 10.1016/S1357-2725(02)00271-6 – ident: e_1_3_4_10_2 doi: 10.1016/j.autrev.2004.07.002 – ident: e_1_3_4_25_2 doi: 10.1139/y02-160 – ident: e_1_3_4_7_2 doi: 10.1172/JCI4106 – ident: e_1_3_4_9_2 doi: 10.1097/00004872-200018070-00017 – ident: e_1_3_4_19_2 doi: 10.2174/156720512801322663 – ident: e_1_3_4_31_2 doi: 10.2165/00007256-200838120-00008 – volume: 62 start-page: 27463 year: 1997 ident: e_1_3_4_20_2 article-title: Topic Q2 (R1): Validation of analytical procedures: text and methodology. International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use. publication-title: Federal Register – ident: e_1_3_4_36_2 doi: 10.1111/j.1532-5415.2007.01186.x – ident: e_1_3_4_13_2 doi: 10.1146/annurev.med.51.1.245 – ident: e_1_3_4_4_2 doi: 10.4049/jimmunol.132.6.2807 – ident: e_1_3_4_11_2 doi: 10.1161/HYPERTENSIONAHA.113.01648 – ident: e_1_3_4_29_2 doi: 10.1172/JCI36703 – volume: 17 start-page: 467 year: 1997 ident: e_1_3_4_5_2 article-title: Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. publication-title: Semin Nephrol contributor: fullname: Weber KT – ident: e_1_3_4_22_2 doi: 10.1089/jir.2010.0043 – ident: e_1_3_4_26_2 doi: 10.1016/S0025-7125(05)70157-7 – ident: e_1_3_4_24_2 doi: 10.1172/JCI4106 – ident: e_1_3_4_2_2 doi: 10.1016/j.peptides.2012.09.016 – ident: e_1_3_4_42_2 doi: 10.1001/jamainternmed.2013.14764 – ident: e_1_3_4_41_2 doi: 10.1016/j.amjhyper.2004.03.306 – ident: e_1_3_4_16_2 doi: 10.1016/S0735-1097(00)01138-4 – ident: e_1_3_4_15_2 doi: 10.1016/j.cellsig.2008.10.011 – ident: e_1_3_4_37_2 doi: 10.1001/archinte.162.20.2333 – volume: 24 start-page: 20 year: 2012 ident: e_1_3_4_12_2 article-title: Activating autoantibodies against the AT1-receptor in vascular disease. publication-title: Transplantationsmedizin contributor: fullname: Dechend R – ident: e_1_3_4_35_2 doi: 10.1056/NEJM200211283472220 – ident: e_1_3_4_34_2 doi: 10.1007/s00251-002-0453-9 – ident: e_1_3_4_33_2 doi: 10.1007/s11906-007-0023-5 – ident: e_1_3_4_30_2 doi: 10.1126/scitranslmed.3002227 – ident: e_1_3_4_3_2 doi: 10.1152/ajpregu.00525.2011 – ident: e_1_3_4_14_2 doi: 10.1089/ars.2006.8.572 |
SSID | ssj0006375 |
Score | 2.392318 |
Snippet | BACKGROUND—Agonistic angiotensin II type I receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health... Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes.... Background: Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health... BACKGROUNDAgonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health... |
SourceID | pubmedcentral proquest crossref pubmed wolterskluwer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 449 |
SubjectTerms | Adult Aged Aged, 80 and over Angiotensin Receptor Antagonists - therapeutic use Autoantibodies - therapeutic use Biomarkers - blood Female Humans Male Middle Aged Treatment Outcome Young Adult |
Title | Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27903588 https://search.proquest.com/docview/1845252245 https://pubmed.ncbi.nlm.nih.gov/PMC5285272 |
Volume | 135 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkCYkhGCDUW7yJMRLlbLEcZw8hnIp08pNHepblDjuiMpi1DZC8Mf4exzbiZvQocFeospJLSfny_E5zufvIPSUqk9jUZ451A254wuSOVnku_Di-YxFOeWZltiYvAvGp_7xjM56vV8t1lK1zob854X7Sq5iVWgDu6pdsv9hWdspNMBvsC8cwcJw_CcbvyxWXFEwjYbSZwipcxsBxmey1CLMg7g8K6QmqqvVekVjkctBXK0lPNQik4pGqKrNvCjkueLqLDW5QxdqXonB-2oNI6-Jho2iQbHkddWvi4r5tBcXshTmTMsDHkyGlrGT1uIFXxd2YvggG4q22q2dDo7t1bNKr7t-BCw7J0V7pcJVlNbGxTfeN3IYMfuQh6J2uJ7v-NQIGlmPbBRMaujRln_1jb5pPVX7Rkx8exYI1CwwevtpdHpiNIXHsWodQsBCTIWgrvL2HzOi5SnqDClwk25Xqi0xXV1D1z0WUZX1v5ltuEUBYbQp4adueBcd1uN6_tdRdQOjrWxnm7R787tUhIrVQu-naEVF09voVp3O4Nhg8w7qiXIP7cdlupbnP_AzrAnG-svNHtqd1DyOfbSwyMWAXLxBLpZzbJGLW8jFDXJxF7k4XeENcvXfDXJxg9y7aPr61XQ0duqyHw4H_0AdnnvgIVhOGfEp8yNVdJLmNIgI5xHJ-JzMvRwSYQhcIdtmri_cIGVuFnLmiTkh99BOKUtxH2EWRAETkLRzCLxz7qX8iIiUgX3mIoPIvI-85pEn34y4S3KpyfvosDFOAq5YfV9LSyGrVeKGiiQAMTFcc2CMZbsFlBwRGoZ9xDpmtBcomffumbL4ouXeqRdSj3l9FHQMnpiN0pcP-MFV7vIhurF5hR-hnfWyEo8h_F5nTzTUfwMmX9Rc |
link.rule.ids | 230,315,786,790,891,27957,27958 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discovery+and+Validation+of+Agonistic+Angiotensin+Receptor+Autoantibodies+as+Biomarkers+of+Adverse+Outcomes&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Abadir%2C+Peter+M.&rft.au=Jain%2C+Alka&rft.au=Powell%2C+Laura+J.&rft.au=Xue%2C+Qian-Li&rft.date=2017-01-31&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=135&rft.issue=5&rft.spage=449&rft.epage=459&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.116.022385&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_CIRCULATIONAHA_116_022385 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |